NS-32 licensing and Phase 1 trial launch
First written in FY2017-Q3. 15 of 20 entries say "Restated". Latest entry: FY2023-Q2.
No other company in this theme has enough history to compare yet.
- FY2023-Q2RestatedAnnual report
「• Licensed the iron deficiency anemia treatment NS-32 (generic name: ferric derisomaltose) from Pharmacosmos (Denmark) in 2016, conducted a Phase 3 trial from March 2019, filed for approval in March 2021, and obtained approval in March 2022.」
Restates the status of NS-32 licensing, the Phase 3 trial, the approval application and approval obtained in March 2022. - FY2023-Q1AchievedAnnual report
「• Licensed the iron deficiency anemia treatment NS-32 (generic name: ferric derisomaltose) from Pharmacosmos (Denmark) in 2016, conducted a Phase 3 trial from March 2019, filed for approval in March 2021, and obtained approval in March 2022.」
NS-32 obtained approval in March 2022 following the Phase 3 trial and approval application. - FY2022-Q3RestatedAnnual report
「Licensed the iron deficiency anemia treatment NS-32 (generic name: ferric derisomaltose) from Pharmacosmos (Denmark) in 2016, conducted a Phase 3 trial from March 2019, and filed for approval in March 2021.」
Restates the status of NS-32 licensing, the Phase 3 trial and the approval application filed in March 2021. - FY2022-Q2RestatedAnnual report
「• Licensed the iron deficiency anemia treatment NS-32 (generic name: ferric derisomaltose) from Pharmacosmos (Denmark) in 2016, conducted a Phase 3 trial from March 2019, and filed for approval in March 2021.」
Restates the status of NS-32 licensing, the Phase 3 trial launched in March 2019 and the approval application filed in March 2021. - FY2022-Q1RestatedAnnual report
「• Licensed the iron deficiency anemia treatment NS-32 (generic name: ferric derisomaltose) from Pharmacosmos (Denmark) in 2016, conducted a Phase 3 trial from March 2019, and filed for approval in March 2021.」
Restates the status of NS-32 licensing, the Phase 3 trial and the approval application filed in March 2021. - FY2021AdvancedAnnual report
「Licensed the iron deficiency anemia treatment NS-32 (generic name: ferric derisomaltose) from Pharmacosmos (Denmark) in 2016, conducted a Phase 3 trial from March 2019, and filed for approval in March 2021.」
NS-32 progressed from the Phase 3 trial stage to the approval application stage in March 2021. - FY2021-Q3RestatedAnnual report
「• Licensed the iron deficiency anemia treatment NS-32 (generic name: ferric derisomaltose) from Pharmacosmos (Denmark) in 2016 and is conducting a Phase 3 trial.」
Restates the status of NS-32 licensing and the ongoing Phase 3 trial. - FY2021-Q2RestatedAnnual report
「• Licensed the iron deficiency anemia treatment NS-32 (generic name: ferric derisomaltose) from Pharmacosmos (Denmark) in 2016 and is conducting a Phase 3 trial.」
Restates the status of NS-32 licensing and the ongoing Phase 3 trial. - FY2021-Q1RestatedAnnual report
「• Licensed the iron deficiency anemia treatment NS-32 (generic name: ferric derisomaltose) from Pharmacosmos (Denmark) in 2016 and is conducting a Phase 3 trial.」
Restates the status of NS-32 licensing and the ongoing Phase 3 trial. - FY2020-Q3RestatedAnnual report
「Licensed the iron deficiency anemia treatment NS-32 (generic name: ferric derisomaltose) from Pharmacosmos (Denmark) in December 2016 and began a Phase 3 trial in March 2019.」
Restates the status of the Phase 3 trial for NS-32, which began in March 2019. - FY2020-Q2RestatedAnnual report
「• Licensed the iron deficiency anemia treatment NS-32 from Pharmacosmos (Denmark) in December 2016 and began a Phase 3 trial in March of this year.」
Restates the status of the Phase 3 trial for NS-32, which began in March 2019. - FY2020-Q1RestatedAnnual report
「• Licensed the iron deficiency anemia treatment NS-32 from Pharmacosmos (Denmark) in December 2016 and began a Phase 3 trial in March of this year.」
Restates the status of the Phase 3 trial for NS-32, which began in March 2019. - FY2019AdvancedAnnual report
「Licensed the iron deficiency anemia treatment NS-32 from Pharmacosmos (Denmark) in December 2016 and began a Phase 3 trial in March of this year.」
NS-32 progressed from the stage of conducting a Phase 1 trial to the stage of launching a Phase 3 trial. - FY2019-Q3AdvancedAnnual report
「• Licensed the iron deficiency anemia treatment NS-32 from Pharmacosmos (Denmark) in December 2016 and is preparing for a Phase 3 trial.」
NS-32 progressed from the previous stage of conducting a Phase 1 trial to the preparation stage for a Phase 3 trial. - FY2019-Q2RestatedAnnual report
「• Licensed the iron deficiency anemia treatment NS-32 from Pharmacosmos (Denmark) in December 2016 and is conducting a Phase 1 trial.」
Restates the status of NS-32 licensing and the ongoing Phase 1 trial. - FY2019-Q1RestatedAnnual report
「• Licensed the iron deficiency anemia treatment NS-32 from Pharmacosmos (Denmark) in December 2016 and is conducting a Phase 1 trial.」
Restates the status of NS-32 licensing and the ongoing Phase 1 trial. - FY2018-Q3RestatedAnnual report
「• In December 2016, licensed the iron deficiency anemia treatment NS-32 from Pharmacosmos (Denmark) and began a Phase 1 trial in January 2017.」
Restates the previous status of NS-32 licensing and the Phase 1 trial that began in January 2017. - FY2018-Q2RestatedAnnual report
「Licensed the iron deficiency anemia treatment NS-32 from Pharmacosmos (Denmark) in December 2016 and began a Phase 1 trial in January 2017.」
Restates the previous status of NS-32 licensing and the Phase 1 trial that began in January 2017. - FY2018-Q1RestatedAnnual report
「• In December 2016, licensed the iron deficiency anemia treatment NS-32 from Pharmacosmos (Denmark) and began a Phase 1 trial in January 2017.」
Restates the previous status of NS-32 licensing and the Phase 1 trial that began in January 2017. - FY2017-Q3First statedAnnual report
「NS-32, a high-dose intravenous iron preparation, was licensed in from PharmaCosmos in Denmark in December 2016, and Phase I trials began in January 2017.」
Licensed NS-32 from Denmark-based Pharmacosmos and launched a Phase 1 trial.